(5R,7R,8S,9S,10R)-1,6-Dioxa-7-(hydroxymethyl)-3-(phenanthren-9-yl)-2-azaspiro[4.5]dec-2-ene-8,9,10-triol

ID: ALA3764195

Chembl Id: CHEMBL3764195

PubChem CID: 127026511

Max Phase: Preclinical

Molecular Formula: C22H21NO6

Molecular Weight: 395.41

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  OC[C@H]1O[C@@]2(CC(c3cc4ccccc4c4ccccc34)=NO2)[C@H](O)[C@@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C22H21NO6/c24-11-18-19(25)20(26)21(27)22(28-18)10-17(23-29-22)16-9-12-5-1-2-6-13(12)14-7-3-4-8-15(14)16/h1-9,18-21,24-27H,10-11H2/t18-,19-,20+,21-,22-/m1/s1

Standard InChI Key:  CVSJVTYANOYZHD-QMCAAQAGSA-N

Alternative Forms

  1. Parent:

    ALA3764195

    ---

Associated Targets(Human)

PYGL Tchem Liver glycogen phosphorylase (1040 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

PYGM Glycogen phosphorylase, muscle form (1331 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Pygl Liver glycogen phosphorylase (81 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 395.41Molecular Weight (Monoisotopic): 395.1369AlogP: 1.29#Rotatable Bonds: 2
Polar Surface Area: 111.74Molecular Species: NEUTRALHBA: 7HBD: 4
#RO5 Violations: 0HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski): 0
CX Acidic pKa: 12.05CX Basic pKa: 2.61CX LogP: 1.66CX LogD: 1.66
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.49Np Likeness Score: 1.22

References

1. Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S..  (2016)  Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.,  108  [PMID:26708111] [10.1016/j.ejmech.2015.12.004]

Source